February 8, 2023 7:39am
CLLS closed offering with proceeds of US$24.76 M ($22.783 M after offering expenses)
Prices its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (ADS), each representing the right to receive one ordinary share of Cellectis, nominal value €0.05 per share , which launched and priced on 2/2/23, at a price to the public of $2.50 per ADS.
Exercise by the underwriters, Jefferies LLC and Barclays Capital Inc., of their option to purchase an additional 1,107,800 ordinary shares of the Company to be delivered in the form of an aggregate of 1,107,800 ADSs.
Interesting: The new ordinary shares underlying the ADSs will be issued through a capital increase without shareholders' pre-emptive rights under the provisions of Article L. 225-136 of the French Commercial Code.
CLLS plans to use approximately $17.0 million (€15.6 million) of the net proceeds of the offering to fund the continued clinical development of UCART 123, UCART22, UCART20x22, and UCARTCS1.
The Bottom Line: the window is open and many are rushing to and hoping through
52-week low of $1.83 and a high of $6.06
52-week change: -46.74%
Revenue: $22.18 M
Cash: $118.18 M
Debt: $89.63 M
Book value per share: $3.00
Total cash per share: $2.61
Shares outstanding: 45.57 M
Float: 33.79 M shares
Shares short (1/13/230: 277.61 K shares
